Please assess the completion status of the following clinical trial:

Trial Title: Medical Polypectomy and Predictors of Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female~* 18-75 years of age~* bilateral nasal polyposis Grade 2 and above~* with or without asthma~* with or without atopy or aspirin sensitivity~* written informed consent~Exclusion Criteria:~* unilateral nasal polyposis~* polypoid lesion suspicious of inverted papilloma, malignancy, Wegeners granulomatosis, sarcoidosis~* known or suspected hypersensitivity to fluticasone propionate or any other constituents of the Investigational Medicinal product (IMP).~* Any clinically significant medical condition or abnormality, which, in the opinion of the investigator, might compromise the safety of the subject or which might interfere with the study.~* significant (≥50%)septal deviation~* inability to comply with the requirements of the protocol~* females who are pregnant, lactating or planning to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
- Prednisolone (Type: EXPERIMENTAL): 25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).